Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure

AIM: The EMPEROR‐Reduced trial demonstrated that empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with a reduced ejection fraction, and the EMPEROR‐Preserved trial is currently evaluating the effect of the drug on the same endpoint in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Packer, Milton, Butler, Javed, Filippatos, Gerasimos, Zannad, Faiez, Ferreira, Joao Pedro, Zeller, Cordula, Brueckmann, Martina, Jamal, Waheed, Pocock, Stuart J., Anker, Stefan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2020
Materias:
Study Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898542/
https://www.ncbi.nlm.nih.gov/pubmed/33251659
http://dx.doi.org/10.1002/ejhf.2065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898542/
https://www.ncbi.nlm.nih.gov/pubmed/33251659
http://dx.doi.org/10.1002/ejhf.2065

Ejemplares similares